Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer. Based on the Zymeworks Inc stock forecasts from 7 analysts, the average analyst target price for Zymeworks Inc is USD 21.00 over the next 12 months. Zymeworks Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Zymeworks Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Zymeworks Inc’s stock price was USD 6.87. Zymeworks Inc’s stock price has changed by +12.07% over the past week, +12.44% over the past month and -77.98% over the last year.

1. Page 1 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ZYME:NYE (Zymeworks Inc)
Biotechnology | NYE | Common Stock
Values as of 30th May, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Last Close
USD 6.87
Change
+0.00(+0.00%)
Market Cap
USD 0.40B
1 Yr Capital Gain
-77.98%
1 Yr Dividend Return
N/A
1 Yr Total
Return
-77.98%
Earning Growth (5 yr)
-698.91%
Average Target Price
21.00(+205.68% )
Average Analyst
Rating
Strong Buy
Fundamental
Analysis
Slightly Bearish
Our view of the stock is Slightly Bearish with a score of 3.3 out of 10, where 0 is very bearish and 10 very bullish
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What to not like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector

2. Page 2 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ZYME:NYE (Zymeworks Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
ZYME
Zymeworks Inc
-78% 0 -78%
VTI
Vanguard Index Funds -
Vanguard Total Stock Market
ETF
-4.6% +1.4% -3.2%
Company Overview
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of
cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials
for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human
epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or
metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and
Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech,
Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and
commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in
Vancouver, Canada.

3. Page 3 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Company Website
https://www.zymeworks.com
Address
114 East 4th Avenue, Vancouver, BC, Canada, V5T 1G4
Fiscal Year End
December
Employees
327
Technical Indicators
Value Value
Beta 1.06 52 Week High 39.41
Short Ratio 2.47 52 Week Low 4.56
Shorted Shares 8,017,050 200 Day Moving Average 16.06
Shorted Shares Previous Month 7,260,299 50 Day Moving Average 6.16
Shares Held By Insiders 711.40% Short Percentage 10.00%
Shares Held by Institutions 89.05 Dividend Yield N/A

4. Page 4 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ZYME:NYE (Zymeworks Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Market Performance
Market Performance vs. Industry / Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain -58.08% -42.2% 17% -10.0% 3%
Dividend Return N/A 0.7% N/A 1.1% N/A
Total Return -58.08% -42.2% 17% -9.3% 3%
Trailing 12 Months
Capital Gain -77.98% -54.9% 26% -8.8% 3%
Dividend Return N/A 1.6% N/A 2.8% N/A
Total Return -77.98% -54.9% 26% -5.9% 3%
Trailing 5 Years
Capital Gain -41.43% -23.6% 33% 10.0% 13%
Dividend Return N/A 9.9% N/A 13.0% N/A
Total Return -41.43% -23.6% 33% 25.2% 10%
Average Annual (5 Year Horizon)
Capital Gain 40.06% 8.1% 75% 4.9% 92%
Dividend Return N/A 1.3% N/A 2.2% N/A
Total Return 40.06% 8.1% 75% 8.0% 92%
Risk Return Profile
Volatility (Standard
Deviation)
76.15% 45.8% 36% 23.1% 10%
Risk Adjusted Return 52.60% N/A 82% 39.9% 65%
Market Capitalization 0.40B 0.08B 80% 1.03B 36%

5. Page 5 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio 300.2 11.6 8% 16.3 3%
pbratio 1.2 1.8 73% 1.6 63%
pcfratio -1.6 -3.2 13% 7.5 81%
pfcfratio N/A 0.3 N/A 10.9 N/A
Management Effectiveness
retequity -72.74% -73.6% 56% 10.0% 4%
retinvcap -51.17% -59.5% 63% 5.6% 4%
retass -33.15% -27.7% 37% 2.5% 1%
debtequityratio N/A 13.6% N/A 68.9% N/A
Technical Ratios
yield N/A 1.5% N/A 3.1% N/A
sratio 2.47 4.26 67% 2.07 43%
spercent 13.88% 3.2% 20% 3.7% 25%
beta 1.06 1.38 63% 1.03 48%

6. Page 6 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ZYME:NYE (Zymeworks Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Maintains SVB Leerink Outperform USD 18 » USD 19 2022-05-27
Maintains HC Wainwright Buy USD 44 » USD 40 2022-05-23
Upgraded by Guggenheim Securities Neutral » Buy USD 14 2022-05-05
Initiated by Evercore ISI Outperform USD 15 2022-03-15
Target Lowered by Citigroup USD 53 » USD 30 2022-02-28
Maintains Wells Fargo Overweight USD 56 » USD 48 2022-02-09
Target Lowered by Raymond James Capital Outperform USD 50 » USD 27 2022-02-01
Target Lowered by Raymond James Capital Outperform USD 74 » USD 50 2022-01-20
Target Set by Raymond James Capital Outperform USD 74 2022-01-06
Downgrades Raymond James Capital Outperform USD 74 2021-12-10
Upgrades SVB Leerink Outperform 2021-12-10
Reiterated by SVB Leerink Hold USD 43 2021-11-15
Initiated by SVB Leerink Hold USD 43 » USD 27 2021-11-04
Reiterated by Wells Fargo Buy USD 56 2021-09-30
Target Set by Raymond James Capital Strong-Buy USD 74 2021-08-06
Reiterated by HC Wainwright Buy USD 55 » USD 44 2021-08-05
Target Lowered by HC Wainwright Buy USD 57 » USD 55 2021-05-07
Initiates Coverage On Credit Suisse Outperform USD 55 2021-03-31
Initiated by Credit Suisse Outperform 2021-03-30
Downgrades SVB Leerink Market Perform USD 50 » USD 41 2021-02-25
Reiterated by HC Wainwright Buy USD 57 2021-02-08
Target Lowered by SVB Leerink Outperform USD 66 » USD 50 2021-01-28
Target Lowered by Wells Fargo USD 71 » USD 56 2021-01-28
Target Lowered by Barclays Equal Weight USD 47 » USD 38 2021-01-28
Downgrades Citigroup Neutral USD 50 » USD 53 2021-01-25

7. Page 7 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ZYME:NYE (Zymeworks Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Annual Financial (USD)

8. Page 8 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ZYME:NYE (Zymeworks Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Quarterly Financial (USD)

9. Page 9 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
ZYME:NYE (Zymeworks Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 31st May, 2022
Largest Industry Peers for Biotechnology
Symbol Company Name Price(Change) Market Cap
NVO Novo Nordisk A/S N/A USD 246.18B
BHVN Biohaven Pharmaceutical Holdin.. N/A USD 10.19B
DNA Ginkgo Bioworks Holdings N/A USD 5.70B
RCUS Arcus Biosciences Inc N/A USD 1.38B
MYOV Myovant Sciences Ltd N/A USD 1.03B
ADCT ADC Therapeutics SA N/A USD 0.57B
PFNX Pfenex Inc N/A USD 0.44B
LCTX Lineage Cell Therapeutics Inc N/A USD 0.22B
MTNB Matinas BioPharma Holdings Inc N/A USD 0.16B
AMAM Ambrx Biopharma Inc. N/A USD 0.16B
ETFs Containing ZYME
Symbol Company Name Weight Mer Price(Change) Market Cap
SCAP AdvisorShares Cornerstone Smal.. 0.00 % 0.90 % N/A USD 3.59M
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%